The monophosphoryl lipid A (MPL), a TLR4 agonist, possesses a well-described adjuvant activity, and it is utilized as a component of adjuvants contained in licensed vaccines [14] (https://www.shingrix.com/; https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk (accessed on 30 May 2023)). This evidence concerns the gene TLR4 and malaria.